Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Codis moves commercial-scale ASD spray-drying expansion into construction

Company / institutional announcement · Codis

Source published:

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What changed

Codis has moved its Haverhill expansion into construction after completing demolition of redundant facilities. The project will add a solvent-capable GEA PSD-4 spray dryer for commercial-scale amorphous solid dispersions and connect with formulation, analytical, clinical supply, and oral solid dose services in Nottingham. Additional capacity is expected in the fourth quarter of 2027, after installation and validation.

Why it may matter

Sponsors developing poorly soluble drugs gain a potential future ASD supply option, although equipment acceptance and validation remain key execution milestones.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Formulation Development & Manufacturing

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Related updates

Nature Communications

Peptide–oligonucleotide nanohybrids deliver miRNA to injured bone in rats

A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.

U.S. Food and Drug Administration

FDA grants accelerated approval for subcutaneous amivantamab combination in selected head and neck cancers

FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and an anti-PD-(L)1 antibody. HPV-associated oropharyngeal cancer is excluded. In the 102-patient OrigAMI-4 efficacy population, response rate was 42%. Continued approval requires confirmatory clinical benefit; this is not traditional full approval.

Phillips Medisize / Business Wire

Phillips Medisize acquires full Chippenham site footprint for inhalation development

Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗